Annual Biopharma Fee Estimates Need More Transparency, BIO Says
Executive Summary
The biopharmaceutical industry is pushing for greater transparency around the data used by the federal government to generate preliminary estimates of the market-based fees owed to the government by individual manufacturers and importers in 2011.